TPCW
ACAD icon

TD Private Client Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

TD Private Client Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21
Closed -$512 – 1212
2021
Q2 		$512 Buy
+21
New +$474 ﹤0.01% 1178

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Private Client Wealth's ACAD Position: Q3 2021 in Review

TD Private Client Wealth sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 21 shares — an estimated $512 sold.

TD Private Client Wealth first reported a position in ACAD in Q2 2021 and held it in 1 quarter. The position peaked at $512 in Q2 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

  • TD Private Client Wealth reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 21 Acadia Pharmaceuticals shares in Q3 2021, an estimated $512.
  • TD Private Client Wealth first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • TD Private Client Wealth's Acadia Pharmaceuticals position peaked at $512 in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on TD Private Client Wealth's 13F filing for Q3 2021, filed 16 Aug 2024.